Capsulution signs cooperation agreement with Schering and AcriTec


Capsulution NanoScience AG has signed a cooperation agreement with Schering AG and Acri.Tec GmbH. The cooperation project is supported by the German Federal Ministry of education and Research (BMBF). Goal of the cooperation is the development of advanced drug delivery systems designed for a more effective application of drugs.

Within the next three years, the companies will concentrate on special hydro-gels that on the one hand have the quality for best possible usage and transport and on the other hand are capable for the controlled release of embedded nanoparticles. These nanoparticles contain active substances and the release of them can take place via a controlled time frame. The combination of functional hytro-gels and embedded nanoparticles enables a targeted release of active substances, which reduces the dosage frequency of the application and increases the therapy safety.

Two different indications of pharmacotherapy are within the focus of the development cooperation. One application is the contraception and treatment of various gynaecological diseases. And the other application is the therapy of retinal removal. Both application areas have special demands for drug-delivery-systems, but pursue the similar approach to nano-functional hydro-gels (NanoGel). The challenge of the cooperation is to determine the exact specification of hydro-gel and nanoparticle characteristics and to establish appropriate in-vitro systems.

The cooperation processes all interdisciplinary aspects from the research of polymers, development of drug-delivery-systems, clinical developments up to the manufacture of products. In this context there are further German research partners included to the project such as the Fraunhofer Institute for Applied Polymer Research IAP, the University of Regensburg and the ITEMP of the medical department of the Aachen University of Technology.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances